BackgroundVenous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to describe the adequacy of antithrombotic prophylaxis (ATP) in hospitalized patients as the initial stage of a program designed to improve physician adherence to –ATP recommendations in Argentina.MethodsThis study was a multicenter, cross-sectional study that included 28 Institutions throughout 5 provinces in Argentina.Results1315 patients were included, 729 (55.4%) were hospitalized for medical (clinical) reasons, and 586 (44.6%) for surgical reasons. Adequate ATP was provided to 66.9% of the patients and was more frequent in surgical (71%) compared to clinical (63.6%) subjects (p < 0.001). Inadequate ATP resulted from underuse in 76.6% of the patients. Among clinical, 203 (16%) had increased bleeding risk and mechanical ATP was used infrequently.ConclusionsThe adequacy of ATP was better in low VTE risk clinical and surgical patients and high VTE risk in orthopedic patients. There was worse adequacy in high risk patients (with active neoplasm) and in those with pharmacological ATP contraindications, in which the use of mechanical methods was scarce. The adequacy of ATP was greater at institutions with < 150 beds compared with larger institutions. This is the first multicentric study reporting ATP in Argentina. Understanding local characteristics of medical performance within our territory is the first step in order to develop measures for improving ATP in our environment.
PET CT adapted treatment for first line Hodgkin Lymphoma has been widely studied in the last decades. Long-term follow-up is important to judge both efficacy and safety of this approach.Patients and Methods: We analyzed updated follow-up data on all patients (pts.) treated within the LH-05 GATLA trial. Newly diagnosed pts. with HL Stages I-IV were included. All patients received 3 ABVD and were evaluated with a PET-CT (PET-CT+3). Pts. with a negative PET-CT+3 (DS 1 and 2) were considered in metabolic CR and received no further therapy. Pts with DS 3 and 4 completed 6 ABVD and IFRT on PET-CT positive areas. Pts with progressive disease (DS 5) after 3 ABVD received salvage chemotherapy. With a median age of 35 yrs., 300 presented with localized stage and 190 with advanced stage.
Results:In LH-05 of all pts. 338 (69%) achieved CR with negative PET-CT+3, 152 (31 %) were PET-CT+3 positive. With a median follow up of 120 months the EFS and OS for all pts. at 5 years is 79.2% and 94.3% respectively. Pts with negative PET-CT+3 had an EFS of 89% and 80% for localized and advanced stage, compared to 63% for 276 -SUPPLEMENT ABSTRACTS all pts. with positive PET-CT+3 (p < 0.0001). We perform a multivariate analysis for EFS which included age, stage, IPS, bulky disease, extranodal areas and the result of the PET+3. This last parameter together with age were the only ones with statistical significance (p = 0.001 and 0.046 respectively). Stage at diagnosis was not significant.With long term follow up the OS at 5 years is 97.3% and 87.3% for all PET+3 negative vs PET+3 positive pts.When comparing the results LH-05 with our previous clinical trial (LH-96) there is no difference in EFS and OS at 5 years but in LH-05 only 31% received more than 3 cycles of ABVD and IFRT compared to 61% and 100% in LH-96. This PET adapted approach reduces exposure to chemo and radiotherapy with no negative effect on long term outcome.
Conclusion:This long term follow up data support the PET-CT adapted approach for all stages of HL after a short course of ABVD. In the Cox regression model, PET-CT at completion of treatment was the most significant factor associated to EFS.Treatment with 3 cycles of ABVD can be adequate for pts. with negative PET-CT+3 regardless their stage at diagnosis. Nevertheless, this long term follow up demonstrated that there is still room for improvement trying to identify PET-CT+3 negative patients that will relapse and escalating treatment in PET-CT+3 positive patients to improve outcome. GATLA is designing a trial with the aim to improve these two different risk groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.